ID

12650

Description

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT; ODM derived from: https://clinicaltrials.gov/show/NCT00840853

Link

https://clinicaltrials.gov/show/NCT00840853

Keywords

Versions (1)
  1. 12/7/15 12/7/15 -
Uploaded on

December 7, 2015

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Acute Lymphoblastic Leukemia (ALL) NCT00840853

English

Eligibility Acute Lymphoblastic Leukemia (ALL) NCT00840853

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)
Description

any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)

Data type

boolean

Alias
UMLS CUI [1]
C2698589
UMLS CUI [2]
C0006413
UMLS CUI [3]
C1705576
or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b).
Description

or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b)

Data type

boolean

Alias
UMLS CUI [1]
C2698589
UMLS CUI [2]
C0023434
UMLS CUI [3]
C0024305
UMLS CUI [4]
C1705576
with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)
Description

with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)

Data type

boolean

Alias
UMLS CUI [1]
C0543478
UMLS CUI [2]
C0277556
with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort
Description

with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort

Data type

boolean

Alias
UMLS CUI [1]
C0153876
UMLS CUI [2]
C1705576
patients with life expectancy greater than or equal to 6 weeks
Description

life expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
patients with a karnofsky/lansky score greater than or equal to 50
Description

karnofsky/lansky score

Data type

boolean

Alias
UMLS CUI [1]
C0206065
donor hiv negative
Description

donor hiv negative

Data type

boolean

Alias
UMLS CUI [1]
C0481430
5. patient or parent/guardian capable of providing informed consent
Description

informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0
Description

patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0

Data type

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0428321
UMLS CUI [3]
C0201976
UMLS CUI [4]
C0019046
pulse oximetry of greater than 90 percent on room air
Description

pulse oximetry

Data type

boolean

Alias
UMLS CUI [1]
C0034108
sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.
Description

sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.

Data type

boolean

Alias
UMLS CUI [1]
C0700589
available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*
Description

available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*

Data type

boolean

Alias
UMLS CUI [1]
C2981182
UMLS CUI [2]
C0201622
patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study.
Description

study subject participation status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers.
Description

note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers

Data type

boolean

Alias
UMLS CUI [1]
C0005771
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
severe intercurrent infection
Description

infection

Data type

boolean

Alias
UMLS CUI [1]
C0009450
evidence of graft versus host disease >grade ii
Description

graft versus host disease

Data type

boolean

Alias
UMLS CUI [1]
C0018133
pregnant or lactating
Description

pregnant or lactating

Data type

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
history of hypersensitivity reactions to murine protein-containing products.
Description

history of hypersensitivity reactions to murine protein-containing products.

Data type

boolean

Alias
UMLS CUI [1]
C0020517
UMLS CUI [2]
C1699668
currently taking corticosteroids for therapy of gvhd.
Description

corticosteroids gvhd

Data type

boolean

Alias
UMLS CUI [1]
C0149783
Back to the top of the page

Similar models

Eligibility Acute Lymphoblastic Leukemia (ALL) NCT00840853

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)
Item
any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)
boolean
C2698589 (UMLS CUI [1])
C0006413 (UMLS CUI [2])
C1705576 (UMLS CUI [3])
or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b)
Item
or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b).
boolean
C2698589 (UMLS CUI [1])
C0023434 (UMLS CUI [2])
C0024305 (UMLS CUI [3])
C1705576 (UMLS CUI [4])
with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)
Item
with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)
boolean
C0543478 (UMLS CUI [1])
C0277556 (UMLS CUI [2])
with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort
Item
with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort
boolean
C0153876 (UMLS CUI [1])
C1705576 (UMLS CUI [2])
life expectancy
Item
patients with life expectancy greater than or equal to 6 weeks
boolean
C0023671 (UMLS CUI [1])
karnofsky/lansky score
Item
patients with a karnofsky/lansky score greater than or equal to 50
boolean
C0206065 (UMLS CUI [1])
donor hiv negative
Item
donor hiv negative
boolean
C0481430 (UMLS CUI [1])
informed consent
Item
5. patient or parent/guardian capable of providing informed consent
boolean
C0021430 (UMLS CUI [1])
patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0
Item
patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0
boolean
C1278039 (UMLS CUI [1])
C0428321 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0019046 (UMLS CUI [4])
pulse oximetry
Item
pulse oximetry of greater than 90 percent on room air
boolean
C0034108 (UMLS CUI [1])
sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.
Item
sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.
boolean
C0700589 (UMLS CUI [1])
available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*
Item
available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*
boolean
C2981182 (UMLS CUI [1])
C0201622 (UMLS CUI [2])
study subject participation status
Item
patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study.
boolean
C2348568 (UMLS CUI [1])
note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers
Item
note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers.
boolean
C0005771 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
infection
Item
severe intercurrent infection
boolean
C0009450 (UMLS CUI [1])
graft versus host disease
Item
evidence of graft versus host disease >grade ii
boolean
C0018133 (UMLS CUI [1])
pregnant or lactating
Item
pregnant or lactating
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
history of hypersensitivity reactions to murine protein-containing products.
Item
history of hypersensitivity reactions to murine protein-containing products.
boolean
C0020517 (UMLS CUI [1])
C1699668 (UMLS CUI [2])
corticosteroids gvhd
Item
currently taking corticosteroids for therapy of gvhd.
boolean
C0149783 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial